These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 15701839)
1. Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients. Chao TY; Yu JC; Ku CH; Chen MM; Lee SH; Janckila AJ; Yam LT Clin Cancer Res; 2005 Jan; 11(2 Pt 1):544-50. PubMed ID: 15701839 [TBL] [Abstract][Full Text] [Related]
2. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis. Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059 [TBL] [Abstract][Full Text] [Related]
3. Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients. Yao NS; Wu YY; Janckila AJ; Ku CH; Hsieh AT; Ho CL; Lee SH; Chao TY Clin Chim Acta; 2011 Jan; 412(1-2):181-5. PubMed ID: 20932965 [TBL] [Abstract][Full Text] [Related]
4. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment. Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696 [TBL] [Abstract][Full Text] [Related]
5. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients. Tang C; Liu Y; Qin H; Li X; Guo W; Li J; Wang W; Qu L; Hu H; Xu C; Zheng L; Huang Y; Liu B; Gao H; Halleen JM; Liu X Clin Chim Acta; 2013 Nov; 426():102-7. PubMed ID: 24055775 [TBL] [Abstract][Full Text] [Related]
6. Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer. Wada N; Ishii S; Ikeda T; Enomoto K; Kitajima M Anticancer Res; 1999; 19(5C):4515-21. PubMed ID: 10650803 [TBL] [Abstract][Full Text] [Related]
7. Age-related changes of serum tartrate-resistant acid phosphatase 5b and the relationship with bone mineral density in Chinese women. Qin YJ; Zhang ZL; Zhang H; Hu WW; Liu YJ; Hu YQ; Li M; Gu JM; He JW Acta Pharmacol Sin; 2008 Dec; 29(12):1493-8. PubMed ID: 19026169 [TBL] [Abstract][Full Text] [Related]
8. Detection of Bone Metastases in Breast Cancer (BC) Patients by Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b), a Bone Resorption Marker and Serum Alkaline Phosphatase (ALP), a Bone Formation Marker, in Lieu of Whole Body Skeletal Scintigraphy with Technetium99m MDP. Sarvari BK; Sankara Mahadev D; Rupa S; Mastan SA Indian J Clin Biochem; 2015 Jan; 30(1):66-71. PubMed ID: 25646043 [TBL] [Abstract][Full Text] [Related]
9. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. Nenonen A; Cheng S; Ivaska KK; Alatalo SL; Lehtimäki T; Schmidt-Gayk H; Uusi-Rasi K; Heinonen A; Kannus P; Sievänen H; Vuori I; Väänänen HK; Halleen JM J Bone Miner Res; 2005 Oct; 20(10):1804-12. PubMed ID: 16355501 [TBL] [Abstract][Full Text] [Related]
10. Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients. Chao TY; Ho CL; Lee SH; Chen MM; Janckila A; Yam LT J Biomed Sci; 2004; 11(4):511-6. PubMed ID: 15153786 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer. Capeller B; Caffier H; Sütterlin MW; Dietl J Anticancer Res; 2003; 23(2A):1011-5. PubMed ID: 12820340 [TBL] [Abstract][Full Text] [Related]
12. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Yamada S; Inaba M; Kurajoh M; Shidara K; Imanishi Y; Ishimura E; Nishizawa Y Clin Endocrinol (Oxf); 2008 Aug; 69(2):189-96. PubMed ID: 18221403 [TBL] [Abstract][Full Text] [Related]
13. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer. Salminen E; Ala-Houhala M; Korpela J; Varpula M; Tiitinen SL; Halleen JM; Väänänen HK Acta Oncol; 2005; 44(7):742-7. PubMed ID: 16227166 [TBL] [Abstract][Full Text] [Related]
14. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis. Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546 [TBL] [Abstract][Full Text] [Related]
15. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer. Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645 [TBL] [Abstract][Full Text] [Related]
16. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Halleen JM Anticancer Res; 2003; 23(2A):1027-9. PubMed ID: 12820342 [TBL] [Abstract][Full Text] [Related]
17. The diagnostic and prognostic value of tartrate-resistant acid phosphatase isoform 5b for giant cell tumor of bone. Toda Y; Ogura K; Iwata S; Kobayashi E; Osaki S; Fukushima S; Mawatari M; Kawai A Int J Clin Oncol; 2024 Sep; 29(9):1391-1397. PubMed ID: 38995462 [TBL] [Abstract][Full Text] [Related]
18. Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer. Lyubimova NV; Pashkov MV; Tyulyandin SA; Gol'dberg VE; Kushlinskii NE Bull Exp Biol Med; 2004 Jul; 138(1):77-9. PubMed ID: 15514730 [TBL] [Abstract][Full Text] [Related]
19. Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis. Chao TY; Wu YY; Janckila AJ Clin Chim Acta; 2010 Nov; 411(21-22):1553-64. PubMed ID: 20599857 [TBL] [Abstract][Full Text] [Related]
20. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Voorzanger-Rousselot N; Juillet F; Mareau E; Zimmermann J; Kalebic T; Garnero P Br J Cancer; 2006 Aug; 95(4):506-14. PubMed ID: 16880790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]